HIV-1 protease: Role in viral replication, protein-ligand x-ray crystal structures and inhibitor design

Aspartic Acid Proteases as Therapeutic Targets

Volumn 45, Issue , 2011, Pages 107-137

  Weber, Irene T ^a   Wang, Yuan Fang ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Aspartic protease; Darunavir; Inhibitor; Polyprotein; Saquinavir

Indexed keywords

EID: 85017479007     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527630943.ch5     Document Type: Chapter

References (114)

1. UNAIDS/WHO 2008 Report on the global AIDS epidemic. http://www. unaids.org/en/KnowledgeCentre/ HIVData/GlobalReport/2008/ 2008. _Global_report.asp.
2. Girard, M.P. and Bansal, G.P. (2008) HIV/AIDS vaccines: a need for new concepts? International Reviews of Immunology, 27, 447-471.
3. Buonaguro, L., Tornesello, M.L., and Buonaguro, F.M. (2007) Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. Journal of Virology, 81, 10209. -10219.
4. Temesgen, Z., Warnke, D., and Kasten, M.J. (2006) Current status of antiretroviral therapy. Expert Opinion on Pharmacotherapy, 7, 1541-1554.
5. Wilson, L.E. andGallant, J.E. (2009) HIV/ AIDS: the management of treatmentexperienced HIV-infected patients: new drugs and drug combinations. Clinical Infectious Diseases, 48, 214-221.
6. Wlodawer, A. and Vondrasek, J. (1998) Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annual Review of Biophysics and Biomolecular Structure, 27, 249-284.
7. Salzwedel, K.,Martin, D.E., and Sakalian, M. (2007) Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Reviews, 9, 162-172.
8. Brenner, B.G., Turner, D., and Wainberg, M.A. (2002) HIV-1 drug resistance: can we overcome? Expert Opinion on Biological Therapy, 2, 751-761.
9. Tozser, J. and Oroszlan, S. (2003) Proteolytic events of HIV-1 replication as targets for therapeutic intervention. Current Pharmaceutical Design, 9, 1803. -1815.
10. Louis, J.M., Weber, I.T., Tozser, J., Clore, G.M., and Gronenborn, A.M. (2000) HIV-1 protease: maturation, enzyme specificity, and drug resistance. Advances in Pharmacology, 49, 111-146.
11. Louis, J., Clore, G., and Gronenborn, A. (1999) Autoprocessing of HIV-1 protease is tightly coupled to protein folding. nature'structural Biology, 6, 868-875.
12. Paulus, C., Ludwig, C., and Wagner, R. (2004) Contribution of the Gag-Pol transframe domain p6 and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1. Virology, 330, 271-283.
13. Chatterjee, A., Mridula, P., Mishra, R., Mittal, R., and Hosur, R. (2005) Folding regulates autoprocessing of HIV-1 protease precursor. The Journal of Biological Chemistry, 280, 11369-11378.
14. Pettit, S.C., Moody, M.D., Wehbie, R.S., Kaplan, A.H., Nantermet, P.V., Klein, C.A., and Swanstrom, R. (1994) The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. Journal of Virology, 68, 8017-8027.
15. Pettit, S.C., Henderson, G.J., Schiffer, C.A., and Swanstrom, R. (2002) Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. Journal of Virology, 76, 10226. -10233.
16. Wiegers, K., Rutter, G., Kottler, H., Tessmer, U., Hohenberg, H., and Krausslich, H.G. (1998) Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. Journal of Virology, 72, 2846. -2854.
17. Louis, J.M., Nashed, N.T., Parris, K.D., Kimmel, A.R., and Jerina, D.M. (1994) Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein. Proceedings of the National Academy of Sciences of the United States of America, 91, 7970-7974.
18. Louis, J.M., Wondrak, E.M., Kimmel, A.R., Wingfield, P.T., and Nashed, N.T. (1999) Proteolytic processing of HIV-1 protease precursor, kinetics and mechanism. The Journal of Biological Chemistry, 274, 23437-23442.
19. Pettit, S.C., Everitt, L.E., Choudhury, S., Dunn, B.M., and Kaplan, A.H. (2004) Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. Journal of Virology, 78, 8477-8485.
20. Pettit, S., Lindquist, J., Kaplan, A., and Swanstrom, R. (2005) Processing sites in the human immunodeficiency virus type 1. (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology, 2, 66-71.
21. Martin, D.E., Salzwedel, K., and Allaway, G.P. (2008) Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antiviral Chemistry & Chemotherapy, 19, 107-113.
22. Li, F., Goila-Gaur, R., Salzwedel, K., Kilgore, N.R., Reddick, M.,Matallana, C., Castillo, A., Zoumplis, D., Martin, D.E., Orenstein, J.M., Allaway, G.P., Freed, E.O. and Wild, C.T., (2003) PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proceedings of the National Academy of Sciences of the United States of America, 100, 13555-13560.
23. Adamson, C.S., Ablan, S.D., Boeras, I., Goila-Gaur, R., Soheilian, F., Nagashima, K., Li, F., Salzwedel, K., Sakalian, M., Wild, C.T., and Freed, E.O. (2006) In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). Journal of Virology, 80, 10957-10971.
24. Darke, P.L., Nutt, R.F., Brady, S.F., Garsky, V.M., Ciccarone, T.M., Leu, C.T., Lumma, P.K., Freidinger, R.M., Veber, D.F., and Sigal, I.S. (1988) HIV-1 protease specificity of peptide cleavage is sufficient for processing of Gag and Pol polyproteins. Biochemical and Biophysical Research Communications, 156, 297-303.
25. Tie, Y., Boross, P.I., Wang, Y.F., Gaddis, L., Liu, F., Chen, X., Tozser, J., Harrison, R.W., and Weber, I.T. (2005) Molecular basis for substrate recognition and drug resistance from 1.1 to 1. 6 Angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS Journal, 272, 5265-5277.
26. Prabu-Jeyabalan, M., Nalivaika, E., and Schiffer, C.A. (2002) Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure, 10, 369-381.
27. Beck, Z.Q., Morris, G.M., and Elder, J.H. (2002) Defining HIV-1 protease substrate selectivity. Current Drug Targets: Infectious Disorders, 2, 37-50.
28. Bagossi, P., Sperka, T., Feher, A., Kadas, J., Zahuczky, G., Miklossy, G., Boross, P., and Tozser, J. (2005) Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites. Journal of Virology, 79. , 4213-4218.
29. Wlodawer, A. and Gustchina, A. (2000) Structural and biochemical studies of retroviral proteases. Biochimica et Biophysica Acta, 1477, 16-34.
30. Dunn, B.M., Goodenow, M.M., Gustchina, A., and Wlodawer, A. (2002) Retroviral proteases. Genome Biology, 3, 3006. .1-3006.7.
31. Vondrasek, J. and Wlodawer, A. (2002) HIVdb: a database of the structures of human immunodeficiency virus protease. Proteins, 49, 429-431.
32. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., and Bourne, P.E. (2000) The Protein Data Bank. Nucleic Acids Research, 28, 235-242.
33. Louis, J.M., Ishima, R., Torchia, D.A., and Weber, I.T. (2007) HIV-1 protease: structure, dynamics, and inhibition. Advances in Pharmacology, 55, 261. -298.
34. Weber, I.T., Kovalevsky, A.Y., and Harrison, R.W. (2007) Structures of HIV protease guide inhibitor design to overcome drug resistance, in Frontiers in Drug Design & Discovery, vol. 3 (eds G.W. Caldwell, Atta-ur-Rahman, M.R. Player, and M.I. Choudhary), Bentham Science Publishers, pp. 45-62.
35. Navia, M.A., Fitzgerald, P.M., McKeever, B.M., Leu, C.T., Heimbach, J.C., Herber, W.K., Sigal, I.S., Darke, P.L., and Springer, J.P. (1989) Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature, 337, 615-620.
36. Wlodawer, A., Miller, M., Jaskolski, M., Sathyanarayana, B.K., Baldwin, E., Weber, I.T., Selk, L.M., Clawson, L., Schneider, J., and Kent, S.B. (1989) Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science, 245, 616-621.
37. Lapatto, R., Blundell, T., Hemmings, A., Overington, J., Wilderspin, A., Wood, S., Merson, J.R., Whittle, P.J., Danley, D.E., Geoghegan, K.F., Hawrylik, S.J., Edward Lee, S., Scheld, K.G., and Hobart, P.M. (1989) X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes' Nature, 342, 299-302.
38. Miller, M., Schneider, J., Sathyanarayana, B.K., Toth, M.V., Marshall, G.R., Clawson, L., Selk, L., Kent, S.B., and Wlodawer, A. (1989) Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Å resolution. Science, 246, 1149-1152.
39. Reiling, K.K., Endres, N.F., Dauber, D.S., Craik, C.S., and Stroud, R.M. (2002) Anisotropic dynamics of the JE-2147-HIV protease complex: drug resistance and thermodynamic binding mode examined in a 1.09 Å structure. Biochemistry, 41, 4582-4594.
40. Brynda, J., Rezacova, P., Fabry, M., Horejsi, M., Stouracova, R., Sedlacek, J., Soucek, M., Hradilek, M., Lepsik, M., and Konvalinka, J. (2004) A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution. Journal of Medicinal Chemistry, 47, 2030. -2036.
41. Tie, Y., Boross, P.I., Wang, Y.F., Gaddis, L., Hussain, A.K., Leshchenko, S., Ghosh, A.K., Louis, J.M.,Harrison, R.W., and Weber, I.T. (2004) High resolution crystal structures ofHIV-1 protease with a potent non-peptide inhibitor (UIC-94017. ) active against multi-drugresistant clinical strains. Journal of Molecular Biology, 338, 341-352.
42. Liu, F., Boross, P.I.,Wang, Y.F., Tozser, J., Louis, J.M., Harrison, R.W., and Weber, I.T. (2005) Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. Journal of Molecular Biology, 354, 789. -800.
43. Tie, Y., Kovalevsky, A.Y., Boross, P., Wang, Y.F., Ghosh, A.K., Tozser, J., Harrison, R.W., and Weber, I.T. (2007) Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Proteins, 67, 232. -242.
44. Kovalevsky, A.Y., Liu, F., Leshchenko, S., Ghosh, A.K., Louis, J.M.,Harrison, R.W., and Weber, I.T. (2006) Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. Journal of Molecular Biology, 363, 161-173.
45. Zoete, V., Michielin, O., and Karplus, M. (2002) Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. Journal of Molecular Biology, 315, 21-52.
46. Rao, J.K., Erickson, J.W., and Wlodawer, A. (1991) Structural and evolutionary relationships between retroviral and eucaryotic aspartic proteinases. Biochemistry, 30, 4663-4671.
47. Gustchina, A. and Weber, I.T. (1990) Comparison of inhibitor binding in HIV-1. protease and in non-viral aspartic proteases: the role of the flap. FEBS Letters, 269, 269-272.
48. Liu, F., Kovalevsky, A.Y., Louis, J.M., Boross, P.I., Wang, Y.F., Harrison, R.W., and Weber, I.T. (2006) Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. Journal of Molecular Biology, 358, 1191. -1199.
49. Prabu-Jeyabalan, M., Nalivaika, E.A., Romano, K., and Schiffer, C.A. (2006) Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. Journal of Virology, 80, 3607. -3616.
50. Camarasa, M.J., Velazquez, S., San-Felix, A., Perez-Perez, M.J., and Gago, F. (2006) Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes' Antiviral Research, 71, 260. -267.
51. Hyland, L.J., Tomaszek, T.A. Jr., Roberts, G.D., Carr, S.A., Magaard, V.W., Bryan, H.L., Fakhoury, S.A., Moore, M.L., Minnich, M.D., Culp, J.S., DesJarlais, R.L., and Meek, T.D. (1991) Human immunodeficiency virus-1 protease. 1. Initial velocity studies and kinetic characterization of reaction intermediates by 18O isotope exchange. Biochemistry, 30, 8441-8453.
52. Hyland, L.J., Tomaszek, T.A., Jr., and Meek, T.D. (1991) Human immunodeficiency virus-1 protease. 2. Use ofpH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry, 30, 8454. -8463.
53. Polgar, L., Szeltner, Z., and Boros, I. (1994) Substrate-dependent mechanisms in the catalysis of human immunodeficiency virus protease. Biochemistry, 33, 9351-9357.
54. Porter, D.J., Hanlon, M.H., and Furfine, E.S. (2002) HIV-1 protease: characterization of a catalytically competent enzyme-substrate intermediate. Biochemistry, 41, 1302. -1307.
55. Szeltner, Z. and Polgar, L. (1996) Ratedetermining steps in HIV-1 protease catalysis. The hydrolysis of the most specific substrate. The Journal of Biological Chemistry, 271, 32180-32184.
56. Liu, H., Muller-Plathe, F., and van Gunsteren, W.F. (1996) A combined quantum/classical molecular dynamics study of the catalytic mechanism of HIV protease. Journal of Molecular Biology, 261, 454. -469.
57. Chatfield, D., Eurenius, K., and Brooks, B. (1998) HIV-1 protease cleavage mechanism: a theoretical investigation based on classical MD simulation and reaction path calculations using a hybrid QM/MM potential. Journal of Molecular Structure: THEOCHEM, 423. , 79-92.
58. Piana, S., Bucher, D., Carloni, P., and Rothlisberger, U. (2004) Reaction mechanism of HIV-1 protease by hybrid Car-Parrinello/classical MD simulations. The Journal of Physical Chemistry B, 108, 11139. -11149.
59. Trylska, J., Grochowski, P., and McCammon, J.A. (2004) The role of hydrogen bonding in the enzymatic reaction catalyzed by HIV-1 protease. Protein Science, 13, 513-528.
60. Northrop, D.B. (2001) Follow the protons: a low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases. Accounts of Chemical Research, 34, 790. -797.
61. Dunn, B.M. (2002) Structure and mechanism of the pepsin-like family of aspartic peptidases. Chemical Reviews, 102. , 4431-4458.
62. Mahalingam, B., Louis, J.M., Hung, J., Harrison, R.W., and Weber, I.T. (2001) Structural implications of drug-resistant mutants of HIV-1 protease: highresolution crystal structures of the mutant protease/substrate analogue complexes. Proteins, 43, 455-464.
63. Tyndall, J.D., Pattenden, L.K., Reid, R.C., Hu, S.H., Alewood, D., Alewood, P.F., Walsh, T., Fairlie, D.P., and Martin, J.L. (2008) Crystal structures of highly constrained substrate and hydrolysis products bound to HIV-1 protease. Implications for the catalytic mechanism. Biochemistry, 47, 3736-3744.
64. Kovalevsky, A.Y., Chumanevich, A.A., Liu, F., Louis, J.M., andWeber, I.T. (2007) Caught in the act: the 1.5 Å resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry, 46, 14854. -14864.
65. Torbeev, V.Y., Mandal, K., Terechko, V.A., and Kent, S.B. (2008) Crystal structure of chemically synthesized HIV-1 protease and a ketomethylene isostere inhibitor based on the p2/NC cleavage site. Bioorganic & Medicinal Chemistry Letters, 18. , 4554-4557.
66. Kumar, M., Prashar, V., Mahale, S., and Hosur, M.V. (2005) Observation of a tetrahedral reaction intermediate in the HIV-1 protease-substrate complex. The Biochemical Journal, 389, 365-371.
67. Das, A., Prashar, V.,Mahale, S., Serre, L., Ferrer, J.L., and Hosur, M.V. (2006) Crystal structure of HIV-1 protease in situ product complex and observation of a low-barrier hydrogen bond between catalytic aspartates. Proceedings of the National Academy of Sciences of the United States of America, 103, 18464-18469.
68. Adachi, M., Ohhara, T., Kurihara, K., Tamada, T., Honjo, E., Okazaki, N., Arai, S., Shoyama, Y., Kimura, K.,Matsumura, H., Sugiyama, S., Adachi, H., Takano, K., Mori, Y.,Hidaka, K., Kimura, T.,Hayashi, Y., Kiso, Y., and Kuroki, R. (2009) Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography. Proceedings of the National Academy of Sciences of the United States of America, 106, 4641-4646.
69. Gustchina, A., Sansom, C., Prevost, M., Richelle, J., Wodak, S.Y., Wlodawer, A., and Weber, I.T. (1994) Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures. Protein Engineering, 7, 309-317.
70. Roberts, N.A., Martin, J.A., Kinchington, D., Broadhurst, A.V., Craig, J.C., Duncan, I.B., Galpin, S.A., Handa, B.K., Kay, J., Krohn, A. et al. (1990) Rational design of peptide-based HIV proteinase inhibitors. Science, 248, 358-361.
71. Krohn, A., Redshaw, S., Ritchie, J.C., Graves, B.J., and Hatada, M.H. (1991) Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. Journal of Medicinal Chemistry, 34, 3340. -3342. 72. Dorsey, B.D., Levin, R.B., McDaniel, S.L., Vacca, J.P., Guare, J.P., Darke, P.L., Zugay, J.A., Emini, E.A., Schleif, W.A., Quintero, J.C. et al. (1994) L-735. ,524: the design of a potent and orally bioavailable HIV protease inhibitor. Journal of Medicinal Chemistry, 37. , 3443-3451.
72. Dorsey, B.D., Levin, R.B., McDaniel, S.L., Vacca, J.P., Guare, J.P., Darke, P.L., Zugay, J.A., Emini, E.A., Schleif, W.A., Quintero, J.C. et al. (1994) L-735. ,524: the design of a potent and orally bioavailable HIV protease inhibitor. Journal of Medicinal Chemistry, 37. , 3443-3451
73. Vacca, J.P., Dorsey, B.D., Schleif, W.A., Levin, R.B., McDaniel, S.L., Darke, P.L., Zugay, J., Quintero, J.C., Blahy, O.M., Roth, E. et al. (1994) L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 91, 4096. -4100.
74. Chen, Z., Li, Y., Chen, E., Hall, D.L., Darke, P.L., Culberson, C., Shafer, J.A., and Kuo, L.C. (1994) Crystal structure at 1. .9-Å resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. The Journal of Biological Chemistry, 269, 26344-26348.
75. Palella, F.J., Jr., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., Aschman, D.J., and Holmberg, S.D. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England Journal of Medicine, 338, 853-860.
76. Sepkowitz, K.A. (2001) AIDS: the first 20 years. The New England Journal of Medicine, 344, 1764-1772.
77. Ghosh, A.K., Ramu Sridhar, P., Kumaragurubaran, N., Koh, Y., Weber, I.T., and Mitsuya, H. (2006) Bistetrahydrofuran: a privileged ligand for darunavir and a new generation of HIV protease inhibitors that combat drug resistance. ChemMedChem, 1, 939-950.
78. Panigrahi, S.K. and Desiraju, G.R. (2007) Strong and weak hydrogen bonds in the protein-ligand interface. Proteins, 67, 128. -141.
79. Brandl, M.,Weiss, M.S., Jabs, A., Suhnel, J., and Hilgenfeld, R. (2001) CH± ± ± piinteractions in proteins. Journal of Molecular Biology, 307, 357-377.
80. Steiner, T. and Koellner, G. (2001) Hydrogen bonds with pi-acceptors in proteins: frequencies and role in stabilizing local 3D structures. Journal of Molecular Biology, 305, 535-557.
81. Steiner, T. (2002) Hydrogen bonds from water molecules to aromatic acceptors in very high-resolution protein crystal structures. Biophysical Chemistry, 95, 195. -201.
82. Weber, I.T.,Wu, J., Adomat, J., Harrison, R.W., Kimmel, A.R.,Wondrak, E.M., and Louis, J.M. (1997) Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate: interactions with frequently occurring glutamic acid residue at P20 position of substrates. European Journal of Biochemistry, 249, 523. -530.
83. Todd, M.J., Luque, I., Velazquez-Campoy, A., and Freire, E. (2000) Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry, 39, 11876-11883.
84. Koh, Y., Nakata, H.,Maeda, K., Ogata, H., Bilcer, G., Devasamudram, T., Kincaid, J.F., Boross, P., Wang, Y.F., Tie, Y., Volarath, P., Gaddis, L., Harrison, R.W., Weber, I.T.,Ghosh, A.K., and Mitsuya, H. (2003) Novel bistetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017. (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrobial Agents and Chemotherapy, 47. , 3123-3129.
85. King, N.M., Prabu-Jeyabalan, M., Nalivaika, E.A., Wigerinck, P., de Bethune, M.P., and Schiffer, C.A. (2004) Structural and thermodynamic basis for the binding of TMC114, a nextgeneration human immunodeficiency virus type 1 protease inhibitor. Journal of Virology, 78, 12012-12021.
86. Surleraux, D.L., Tahri, A., Verschueren, W.G., Pille, G.M., de Kock, H.A., Jonckers, T.H., Peeters, A., De Meyer, S., Azijn, H., Pauwels, R., de Bethune, M.P., King, N.M., Prabu-Jeyabalan, M., Schiffer, C.A., and Wigerinck, P.B. (2005) Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. Journal of Medicinal Chemistry, 48, 1813. -1822.
87. Clotet, B., Bellos, N., Molina, J.M., Cooper, D., Goffard, J.C., Lazzarin, A., Wohrmann, A., Katlama, C., Wilkin, T., Haubrich, R., Cohen, C., Farthing, C., Jayaweera, D., Markowitz, M., Ruane, P., Spinosa-Guzman, S., and Lefebvre, E. (2007) Efficacy and safety of darunavirritonavir at week 48 in treatmentexperienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet, 369, 1169. -1178.
88. Kovalevsky, A.Y., Tie, Y., Liu, F., Boross, P.I., Wang, Y.F., Leshchenko, S., Ghosh, A.K., Harrison, R.W., and Weber, I.T. (2006) Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. Journal of Medicinal Chemistry, 49, 1379. -1387.
89. Liu, F., Kovalevsky, A.Y., Tie, Y., Ghosh, A.K., Harrison, R.W., and Weber, I.T. (2008) Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir. Journal of Molecular Biology, 381, 102. -115.
90. Kovalevsky, A.Y., Louis, J.M., Aniana, A., Ghosh, A.K., and Weber, I.T. (2008) Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease. Journal of Molecular Biology, 384, 178. -192.
91. Shafer, R.W. (2006) Rationale and uses of a public HIV drug-resistance database. The Journal of Infectious Diseases, 194 (Suppl. 1), S51-S58.
92. Shafer, R.W. and Schapiro, J.M. (2008) HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Reviews, 10, 67. -84.
93. Rhee, S.Y., Gonzales, M.J., Kantor, R., Betts, B.J., Ravela, J., and Shafer, R.W. (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research, 31, 298-303.
94. Wu, T.D., Schiffer, C.A., Gonzales, M.J., Taylor, J., Kantor, R., Chou, S., Israelski, D., Zolopa, A.R., Fessel,W.J., and Shafer, R.W. (2003) Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. Journal of Virology, 77, 4836. -4847.
95. Johnson, V.A., Brun-Vezinet, F., Clotet, B., Gunthard, H.F., Kuritzkes, D.R., Pillay, D., Schapiro, J.M., and Richman, D.D. (2008) Update of the drug resistance mutations in HIV-1. Topics in HIV Medicine, 16, 138-145.
96. Mitsuya, Y., Winters, M.A., Fessel, W.J., Rhee, S.Y., Hurley, L., Horberg, M., Schiffer, C.A., Zolopa, A.R., and Shafer, R.W. (2006) N88D facilitates the cooccurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Research and Human Retroviruses, 22, 1300-1305.
97. Verheyen, J., Litau, E., Sing, T., Daumer, M., Balduin, M., Oette, M., Fatkenheuer, G., Rockstroh, J.K., Schuldenzucker, U., Hoffmann, D., Pfister, H., and Kaiser, R. (2006) Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-Gag in therapy-naive and therapyexperienced patients. Antiviral Therapy, 11. , 879-887.
98. Shafer, R.W., Rhee, S.Y., Pillay, D., Miller, V., Sandstrom, P., Schapiro, J.M., Kuritzkes, D.R., and Bennett, D. (2007) HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS, 21, 215-223.
99. Ho, S.K., Coman, R.M., Bunger, J.C., Rose, S.L., OBrien, P.,Munoz, I., Dunn, B.M., Sleasman, J.W., and Goodenow, M.M. (2008) Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology, 378, 272. -281.
100. Hurt, C.B., McCoy, S.I., Kuruc, J., Nelson, J.A., Kerkau, M., Fiscus, S., McGee, K., Sebastian, J., Leone, P., Pilcher, C.,Hicks, C., and Eron, J. (2009) Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antiviral Therapy, 14, 673-678.
101. Dauber, D.S., Ziermann, R., Parkin, N., Maly, D.J., Mahrus, S., Harris, J.L., Ellman, J.A., Petropoulos, C., and Craik, C.S. (2002) Altered substrate specificity of drug-resistant humanimmunodeficiency virus type 1 protease. Journal of Virology, 76. , 1359-1368.
102. Mahalingam, B.,Wang, Y.F., Boross, P.I., Tozser, J., Louis, J.M., Harrison, R.W., and Weber, I.T. (2004) Crystal structures of HIVprotease V82A and L90M mutants reveal changes in the indinavir-binding site. European Journal of Biochemistry, 271, 1516. -1524.
103. Ghosh, A.K., Chapsal, B.D., Weber, I.T., and Mitsuya, H. (2008) Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Accounts of Chemical Research, 41, 78-86.
104. Ghosh, A.K., Sridhar, P.R., Leshchenko, S., Hussain, A.K., Li, J., Kovalevsky, A.Y., Walters, D.E., Wedekind, J.E., Grum-Tokars, V., Das, D., Koh, Y., Maeda, K., Gatanaga, H., Weber, I.T., and Mitsuya, H. (2006) Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. Journal ofMedicinal Chemistry, 49. , 5252-5261.
105. Amano, M., Koh, Y., Das, D., Li, J., Leschenko, S., Wang, Y.F., Boross, P.I., Weber, I.T., Ghosh, A.K., and Mitsuya, H. (2007) A novel bistetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065. , is potent against multiple-PIresistant human immunodeficiency virus in vitro. Antimicrobial Agents and Chemotherapy, 51, 2143-2155.
106. Wang, Y.F., Tie, Y., Boross, P.I., Tozser, J., Ghosh, A.K., Harrison, R.W., and Weber, I.T. (2007) Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. Journal of Medicinal Chemistry, 50, 4509. -4515.
107. Ghosh, A.K., Gemma, S., Baldridge, A., Wang, Y.F., Kovalevsky, A.Y., Koh, Y., Weber, I.T., and Mitsuya, H. (2008) Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. Journal of Medicinal Chemistry, 51. , 6021-6033.
108. Ghosh, A.K., Gemma, S., Takayama, J., Baldridge, A., Leshchenko-Yashchuk, S., Miller, H.B.,Wang, Y.F., Kovalevsky, A.Y., Koh, Y., Weber, I.T., and Mitsuya, H. (2008) Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies. Organic and Biomolecular Chemistry, 6, 3703-3713.
109. Ghosh, A.K., Leshchenko-Yashchuk, S., Anderson, D.D., Baldridge, A., Noetzel, M., Miller, H.B., Tie, Y., Wang, Y.F., Koh, Y., Weber, I.T., and Mitsuya, H. (2009) Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P10-ligands to enhance backbonebinding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies. Journal of Medicinal Chemistry, 52, 3902-3914.
110. Ghosh, A.K.,Kulkarni, S.,Anderson, D.D., Hong, L., Baldridge, A., Wang, Y.F., Chumanevich, A.A., Kovalevsky, A.Y., Tojo, Y., Masayuki, A., Koh, Y., Tang, J., Weber, I.T.,andMitsuya,H. (2009)Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance. Journal of Medicinal Chemistry, 52 (23), 7689-7705.
111. Ghosh, A.K. (2009) Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drugresistant HIV to Alzheimer's disease. Journal of Medicinal Chemistry, 52, 2163. -2176.
112. Kovalevsky, A.Y.,Ghosh, A.K., andWeber, I.T. (2008) Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir. Journal of Medicinal Chemistry, 51, 6599-6603.
113. Koh, Y.,Matsumi, S., Das, D., Amano, M., Davis, D.A., Li, J., Leschenko, S., Baldridge, A., Shioda, T., Yarchoan, R., Ghosh, A.K., and Mitsuya, H. (2007) Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. The Journal of Biological Chemistry, 282, 28709. -28720.
114. Weber, I.T., Zhang, Y., and Tozser, J. (2008) HIV-1 protease and AIDS therapy, in Proteases in Biology and Disease, Viral Proteases and Antiviral Protease Inhibitor Therapy, vol. 8 (eds U. Lendeckel and N.M. Hooper), Springer, pp. 25-46.